DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group



    QUEBEC CITY, July 2 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, announced today that Dr. Timothy J. Holzer,
Vice President, R&D and Production at DiagnoCure, and Dr. Scott Waldman, from
Thomas Jefferson University, were speakers on June 29, 2008, in Boston,
Massachusetts, in a session at the Eastern Cooperative Oncology Group (ECOG),
one of the largest clinical cancer research organizations in the United
States. Dr. Holzer and Dr. Waldman discussed with members of the GI
(gastro-intestinal) committee about the importance of DiagnoCure's GCC mRNA
molecular marker in the staging of colorectal cancer.
    Dr. Holzer presented research data on "Molecular Detection of Colorectal
Cancer Lymph Node Micrometastasis". His presentation featured a statistical
review and discussion of the beneficial role of GCC in the staging of
colorectal cancer. Dr. Waldman discussed his discovery and recently completed
clinical studies about the significant staging role of GCC in colorectal
cancer in a talk entitled "Molecular Approaches to Individualized Management
of Cancer".
    GCC is expressed only in intestinal mucosal cells, but not in
extra-intestinal tissues. In addition, GCC is expressed in colorectal tumors,
but not in other cancers outside the gastro-intestinal tract. Therefore, GCC
may be useful clinically for the management of patients with colorectal cancer
in providing more accurate information about lymph node metastasis to
physicians and patients and influencing treatment decisions.

    About Previstage(TM) GCC

    Staging a patient with colorectal cancer is crucial because it determines
the patient's course of treatment. Current standard of care requires that
pathologists examine microscopically a thin slice of tissue from each of 12 or
more lymph nodes harvested during the patient's surgery to see if cancer has
spread beyond the intestine. Currently up to 25 - 30 percent of patients with
no histopathologically-positive lymph nodes (stage I and II cancers) later
return with recurrent disease, presumably through occult metastases that have
escaped detection. Most of these patients do not receive additional treatment
such as chemotherapy. Previstage(TM) GCC aims to provide clinicians with a
significantly more sensitive tool for staging a patient with colorectal
cancer.
    Clinical data from a 5-year prospective clinical study supported the
potential importance of the GCC test in improving the staging of colorectal
cancer patients. This study was sponsored by the National Cancer Institute.
The study has been completed and the Company's collaborators at Thomas
Jefferson University will be presenting the results of the study at major
medical conferences later this year.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. In addition to its own research, the Company
intends to acquire or in-license additional promising cancer biomarkers from
both academic and commercial institutions. For more information, visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF




For further information:

For further information: JF Bureau, Chief Financial Officer, DiagnoCure
Inc., (418) 527-6100, communications@diagnocure.com; Media: U.S.: Troy
Pearson, Mentus Life Science, (858) 455-5500 X320, Troy@mentus.com; Canada:
Jean-Pierre Trudel, Jean-Pierre Trudel & Associates, (514) 347-6111,
jp.trudel@videotron.ca

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890